$1.5M Grant to Fund CBT-I Programs for Insomnia in Brain Cancer Patients

A team of clinical psychologists at VCU Massey Cancer Center received a four-year, $1.5 million grant from the US Department of Defense to help treat insomnia among military members, veterans, their beneficiaries, and the general public who have been diagnosed with brain cancer. Insomnia is common among people with brain cancer, from diagnosis throughout survivorship.…

Read More

How Aripiprazole Tackles Circadian Rhythm Sleep Disorders

While aripiprazole has long been a standard treatment for psychiatric disorders, such as schizophrenia and bipolar disorder, recent studies indicate that it is effective in treating circadian rhythm sleep disorders, including delayed sleep-phase syndrome. However, the precise mechanism through which aripiprazole addresses these sleep disorder symptoms remains elusive. Researchers from the University of Tsukuba have…

Read More

Medical Cannabis Relieves Fatigue, Yet Sleep Disturbances Remain

Australian patients with chronic health issues prescribed medical cannabis showed significant improvements in overall health-related quality of life and fatigue in the first three months of use, along with improvements in anxiety, depression, and pain—but, interestingly, cannabis therapy did not seem to improve reported sleep disturbances. The study was published in PLOS ONE by Margaret-Ann…

Read More

Experimental Insomnia Drug Prevents Oxycodone Relapse 

Scientists who gave an experimental insomnia treatment to rats experiencing oxycodone withdrawal found that the animals were far less likely to seek out drugs again in the future—even after ending the treatment.  The findings, published in Neuropharmacology, could eventually lead to therapies to help prevent opioid addiction or relapse in humans, according to researchers. “These…

Read More

Harmony Gets FDA Orphan Drug Designation for Pitolisant for Idiopathic Hypersomnia

The US Food and Drug Administration (FDA) has granted Harmony Biosciences Orphan Drug Designation for pitolisant for the treatment of idiopathic hypersomnia. Harmony Biosciences is currently evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia in a phase 3 registrational INTUNE study, a double-blind, placebo-controlled, randomized withdrawal study. Topline study results…

Read More